Article
Substance Abuse
Chrianna Bharat, Sarah Larney, Sebastiano Barbieri, Timothy Dobbins, Nicola R. Jones, Matthew Hickman, Natasa Gisev, Robert Ali, Louisa Degenhardt
Summary: The study found that retention in buprenorphine treatment for opioid dependence in New South Wales, Australia has improved over time since its introduction in 2001. Treatment retention is not only influenced by characteristics of the person and their treatment, but also by prescriber characteristics, with longer prescribing tenure associated with increased retention of people in opioid agonist treatment.
Article
Public, Environmental & Occupational Health
Sinisa Skocibusic, Nera Zivlak-Radulovic, Mevludin Hasanovic, Hassan Awad, Dragana Karan-Krizanac, Nermana Mehic-Basara, Tomislav Rukavina
Summary: This study found that opiate addicts on opioid substitution treatment have a higher risk of HCV infection if they have personality dysfunction, particularly in terms of self-respect, enduring relationships, and cooperativity.
FRONTIERS IN PUBLIC HEALTH
(2022)
Article
Environmental Sciences
Andrew W. Bergen, James W. Baurley, Carolyn M. Ervin, Christopher S. McMahan, Joe Bible, Randall S. Stafford, Seshadri C. Mudumbai, Andrew J. Saxon
Summary: This study examines the impact of agonist dose and engagement of physician, staff, and patients on the treatment of opioid use disorder. The findings suggest that higher doses of buprenorphine and increased patient engagement with providers and clinic staff are associated with reduced illicit opiate use.
INTERNATIONAL JOURNAL OF ENVIRONMENTAL RESEARCH AND PUBLIC HEALTH
(2022)
Article
Substance Abuse
Mariah M. Kalmin, David Goodman-Meza, Erik Anderson, Ariana Abid, Melissa Speener, Hannah Snyder, Arianna Campbell, Aimee Moulin, Steve Shoptaw, Andrew A. Herring
Summary: Patients with opioid use disorder are successfully accessing same-day MOUD in CA Bridge hospital settings. Importantly, access to MOUD in these settings is facilitated for patients traditionally not treated using buprenorphine, such as those with housing instability, Medicaid insurance, and co-methamphetamine use.
DRUG AND ALCOHOL DEPENDENCE
(2021)
Article
Gastroenterology & Hepatology
Shari Rogal, Ada Youk, Olufunso Agbalajobi, Hongwei Zhang, Walid Gellad, Michael J. Fine, Pamela Belperio, Timothy Morgan, Chester B. Good, Kevin Kraemer
Summary: Few Veterans with active OUD and cirrhosis received MOUD, and those with alcohol use disorder, schizophrenia, and previous prescriptions for opioids were least likely to receive these effective therapies.
AMERICAN JOURNAL OF GASTROENTEROLOGY
(2021)
Article
Psychiatry
Christopher S. Stauffer, Salem Samson, Alex Hickok, William F. Hoffman, Steven L. Batki
Summary: The increasing prevalence of illicit stimulant use poses a significant risk to public health, especially among those in opioid treatment programs. Oxytocin administration shows promise in enhancing treatment engagement among individuals with stimulant and opioid use disorders. However, it does not significantly affect stimulant use, craving, or therapeutic alliance.
FRONTIERS IN PSYCHIATRY
(2022)
Article
Medicine, General & Internal
Elizabeth J. Austin, Jessica Chen, Elsa S. Briggs, Lori Ferro, Paul Barry, Ashley Heald, Joseph O. Merrill, Geoffrey M. Curran, Andrew J. Saxon, John C. Fortney, Anna D. Ratzliff, Emily C. Williams
Summary: This study explores the experiences and perspectives of multidisciplinary primary care (PC) teams in initiating or expanding medication for opioid use disorder (MOUD). The results suggest that PC teams face challenges in providing rapid access to care and engaging patients with MOUD, as well as maintaining clinician confidence. Attitudes towards MOUD expansion vary among PC teams. The study highlights the need for flexibility in appointment scheduling, effective patient engagement, and ongoing training to address evolving opioid-related clinical issues.
Article
Medicine, General & Internal
Tara Gomes, Tonya J. Campbell, Sophie A. Kitchen, Ria Garg, Nikki Bozinoff, Siyu Men, Mina Tadrous, Charlotte Munro, Tony Antoniou, Dan Werb, Jennifer Wyman
Summary: A retrospective cohort study in Ontario, Canada during the COVID-19 pandemic found that providing increased take-home doses of opioid agonist therapy was associated with lower risks of treatment interruption and discontinuation. The study did not show a significant increase in opioid-related overdoses over 6 months of follow-up.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2022)
Review
Psychology, Clinical
Jessica Moe, Fiona O'Sullivan, Corinne M. Hohl, Mary M. Doyle-Waters, Claire Ronsley, Raymond Cho, Qixin Liu, Pouya Azar
Summary: This systematic review synthesized evidence on the effectiveness and regimens of buprenorphine micro-induction, including 19 case studies/series and one feasibility study. The results showed highly variable regimens with low study quality, limiting conclusions regarding optimal dosing, patient characteristics, and clinical settings for micro-induction. Rigorous studies evaluating effectiveness and safety are needed.
ADDICTIVE BEHAVIORS
(2021)
Article
Anesthesiology
Sarah A. Eidbo, Amalie K. Kropp Lopez, Joseph D. Hagedorn, Varkey Mathew, Daniel E. Kaufman, Stephanie D. Nichols, Kenneth L. McCall, Brian J. Piper
Summary: This study analyzed the trends in opioid distribution by hospitals in the United States and found a decrease in opioid use since 2012. While buprenorphine has increased in hospital use, other opioids have shown a decline. There was a significant difference in opioid use between states in 2019.
Article
Substance Abuse
Jack H. Ching, Douglas K. Owens, Jodie A. Trafton, Jeremy D. Goldhaber-Fiebert, Joshua A. Salomon
Summary: Long-term medication-assisted treatment (MAT) with methadone or buprenorphine is associated with lower all-cause mortality for individuals with opioid use disorder (OUD), with longer treatment durations resulting in greater reductions in mortality.
Article
Substance Abuse
Emma Zahra, Rory Chen, Suzanne Nielsen, Anh Dam Tran, Thomas Santo Jr, Louisa Degenhardt, Michael Farrell, Jude Byrne, Robert Ali, Briony Larance
Summary: The study explores the financial and social impact of dosing fees on Opioid agonist treatment (OAT) clients. The findings reveal that these fees have negative consequences on treatment access and retention, affecting clients' physical health, mental health, and social wellbeing.
DRUG AND ALCOHOL REVIEW
(2022)
Article
Substance Abuse
Laura Checkley, Scott Steiger, Kelly R. Knight
Summary: The study found that patients in an urban hospital-based opioid treatment program chose buprenorphine over methadone primarily due to increased flexibility, decreased sedation, and greater effectiveness in preventing opioid use. However, some patients also encountered challenges during the transition to buprenorphine.
Article
Toxicology
Matthew Zuckerman, Timothy Kelly, Kennon Heard, Amy Zosel, Michael Marlin, Jason Hoppe
Summary: A diverse group of emergency medicine physicians from different practice settings showed substantial support for the implementation of buprenorphine in the treatment of opioid use disorder. Various physicians reported similar barriers to the implementation of buprenorphine across different clinical environments.
CLINICAL TOXICOLOGY
(2021)
Article
Medicine, General & Internal
Julie M. Donohue, Marian P. Jarlenski, Joo Yeon Kim, Lu Tang, Katherine Ahrens, Lindsay Allen, Anna Austin, Andrew J. Barnes, Marguerite Burns, Chung-Chou H. Chang, Sarah Clark, Evan Cole, Dushka Crane, Peter Cunningham, David Idala, Stefanie Junker, Paul Lanier, Rachel Mauk, Mary Joan McDuffie, Shamis Mohamoud, Nathan Pauly, Logan Sheets, Jeffery Talbert, Kara Zivin, Adam J. Gordon, Susan Kennedy
Summary: The study found that the prevalence of medication use for the treatment of opioid use disorder among Medicaid enrollees in 11 states in the US increased from 2014 through 2018. Further research is needed to understand the situation in other states.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
(2021)
Article
Rehabilitation
Allyn M. Bove, Steven T. Gough, Leslie R. M. Hausmann
PHYSIOTHERAPY THEORY AND PRACTICE
(2019)
Article
Medicine, General & Internal
Patience Moyo, Xinhua Zhao, Carolyn T. Thorpe, Joshua M. Thorpe, Florentina E. Sileanu, John P. Cashy, Jennifer A. Hale, Maria K. Mor, Thomas R. Radomski, Julie M. Donohue, Leslie R. M. Hausmann, Joseph T. Hanlon, Chester B. Good, Michael J. Fine, Walid F. Gellad
ANNALS OF INTERNAL MEDICINE
(2019)
Article
Orthopedics
E. R. Vina, L. R. M. Hausmann, D. S. Obrosky, A. Youk, S. A. Ibrahim, D. K. Weiner, R. M. Gallagher, C. K. Kwoh
OSTEOARTHRITIS AND CARTILAGE
(2019)
Article
Rheumatology
Ernest R. Vina, Michael J. Hannon, Leslie R. M. Hausmann, Said A. Ibrahim, Jazmin Dagnino, Andrea Arellano, C. Kent Kwoh
ARTHRITIS CARE & RESEARCH
(2019)
Letter
Geriatrics & Gerontology
Thomas R. Radomski, Walid F. Gellad
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2020)
Article
Geriatrics & Gerontology
Aimee N. Pickering, Megan E. Hamm, Alicia Dawdani, Joseph T. Hanlon, Carolyn T. Thorpe, Walid F. Gellad, Thomas R. Radomski
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2020)
Article
Clinical Neurology
Elizabeth C. S. Swart, Chester B. Good, Rochelle Henderson, Chronis Manolis, Claire Yanta, Natasha Parekh, Lynn M. Neilson
Letter
Geriatrics & Gerontology
Thomas R. Radomski
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2021)
Article
Oncology
Lynn Neilson, Monal Kohli, Kiraat D. Munshi, Samuel Peasah, Rochelle Henderson, Vida Passero, Chester B. Good
Summary: The COVID-19 pandemic has had a significant impact on new cancer diagnoses and the initiation of oral oncology medications. There was a decline in new users of oral breast cancer drugs, while no significant trends were found for leukemia, melanoma, lung, and prostate cancer specific oral medications.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE
(2022)
Article
Medicine, General & Internal
Elizabeth C. S. Swart, Terri Newman, Yan Huang, Robert J. Howell, Mei Han, Chester B. Good, Samuel K. Peasah, Natasha Parekh
Summary: This study aimed to investigate and analyze the factors associated with a new diagnosis of opioid use disorder (OUD) following hospitalization. The study found that patients between the ages of 25 to 34 who received opioids during their hospital stay, as well as those from regions with a high opioid ranking, had a higher likelihood of developing a new diagnosis of OUD. In addition, patients with a history of nonopioid-related drug disorders, tobacco use disorders, mental health conditions, gabapentin use within the previous 12 months, and those of white race also had a higher risk of new OUD diagnosis.
JOURNAL OF HOSPITAL MEDICINE
(2022)
Editorial Material
Geriatrics & Gerontology
Anna Hung, Jinjiao Wang, Frank Moriarty, Veena Manja, Tesfahun Eshetie, Henok Getachew Tegegn, Timothy S. Anderson, Thomas R. Radomski, Michael A. Steinman
JOURNAL OF THE AMERICAN GERIATRICS SOCIETY
(2023)
Article
Cardiac & Cardiovascular Systems
Christopher LaFratte, Samuel K. Peasah, Yan Huang, Deanne Hall, Urvashi Patel, Chester B. Good
Summary: This study evaluates the impact of PCSK9i initiation on statin discontinuation and adherence. The results show that PCSK9i use is associated with decreased low-density lipoprotein cholesterol, increased statin discontinuation, and reduced statin adherence.
JOURNAL OF THE AMERICAN HEART ASSOCIATION
(2023)
Article
Psychology, Clinical
Vicki S. Helgeson, Howard Seltman, Mary T. Korytkowski, Leslie R. M. Hausmann
JOURNAL OF HEALTH PSYCHOLOGY
(2020)
Article
Public, Environmental & Occupational Health
Patience Moyo, Xinhua Zhao, Carolyn T. Thorpe, Joshua M. Thorpe, Florentina E. Sileanu, John P. Cashy, Jennifer A. Hale, Maria K. Mor, Thomas R. Radomski, Julie M. Donohue, Leslie R. M. Hausmann, Joseph T. Hanlon, Chester B. Good, Michael J. Fine, Walid F. Gellad
RESEARCH IN SOCIAL & ADMINISTRATIVE PHARMACY
(2019)